Molecular Pharmacology (USA), Ltd.
MLPH · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 6/30/2014 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | – | – | – | $2 |
| Short-Term Investments | – | – | – | $0 |
| Receivables | – | – | – | $6 |
| Inventory | – | – | – | $0 |
| Other Curr. Assets | – | – | – | $0 |
| Total Curr. Assets | – | – | – | $9 |
| Property Plant & Equip (Net) | – | – | – | $0 |
| Goodwill | – | – | – | $0 |
| Intangibles | – | – | – | $0 |
| Long-Term Investments | – | – | – | $0 |
| Tax Assets | – | – | – | $0 |
| Other NC Assets | – | – | – | $0 |
| Total NC Assets | – | – | – | $0 |
| Other Assets | – | – | – | $0 |
| Total Assets | – | – | – | $9 |
| Liabilities | – | – | – | – |
| Payables | – | – | – | $0 |
| Short-Term Debt | – | – | – | $0 |
| Tax Payable | – | – | – | $0 |
| Deferred Revenue | – | – | – | $0 |
| Other Curr. Liab. | – | – | – | $35 |
| Total Curr. Liab. | – | – | – | $35 |
| LT Debt | – | – | – | $0 |
| Deferred Rev, NC | – | – | – | $0 |
| Deferred Tax Liab, NC | – | – | – | $0 |
| Other NC Liab. | – | – | – | $2,207 |
| Total NC Liab. | – | – | – | $2,207 |
| Other Liabilities | – | – | – | $0 |
| Cap. Leases | – | – | – | $0 |
| Total Liabilities | – | – | – | $2,242 |
| Equity | – | – | – | – |
| Pref Stock | – | – | – | $0 |
| Common Stock | – | – | – | $112 |
| Retained Earnings | – | – | – | -$2,179 |
| AOCI | – | – | – | -$272 |
| Other Equity | – | – | – | $107 |
| Total Equity | – | – | – | -$2,233 |
| Supplemental Information | – | – | – | – |
| Minority Interest | – | – | – | $0 |
| Total Liab. & Tot. Equity | – | – | – | $9 |
| Net Debt | $0 | $0 | $0 | -$2 |